The 2026 Gates Grubstake Awards are accepting applications for translational biomedical projects affiliated with the University of Colorado, Children’s Hospital Colorado, and the UCHealth System. Gates Institute at CU Anschutz states that $1.5 million total is available to support multiple projects, with individual award amounts varying by project funding needs.
The application deadline is September 14, 2026 at 5:00 PM MT. Applications are submitted through the official Gates Grubstake online application platform.
Eligible technology areas
The 2026 call focuses on regenerative medicine and cell/gene therapy technologies, including cell and gene therapies, biologics, small molecules that reprogram cells in situ, stem-cell technologies, devices that induce cell reprogramming or tissue regeneration, and companion diagnostics for those products. Investigators with adjacent programs are also encouraged to apply.
Eligibility and process
Interested investigators affiliated with the University of Colorado, Children’s Hospital Colorado, and the UCHealth System are encouraged to apply. Selected applicants are expected to be notified for presentations in October, with Investment Committee presentations planned for mid-November and award notifications expected in December 2026. The public controlling page does not state a mandatory match or cost-share requirement, a fixed individual award ceiling, or a comprehensive eligible-cost schedule, so Atlas does not infer those terms.
Atlas analysis
Atlas Opportunity Score: 42/100. N9+ Fit: 0/100. QC Healthcare/Dr. Miltie direct-vendor fit: 0/100. This is legitimate Colorado healthcare innovation funding, but its eligible technology classes are regenerative medicine, cell/gene therapy, biologics, reprogramming technologies, and related companion diagnostics. The Nonagon N9+ remote physical examination platform and QC Healthcare clinical services do not fit those classes without forcing fit. Dr. Miltie, LLC is not presented by the controlling source as an eligible direct applicant. Atlas should retain this opportunity for Colorado healthcare funding intelligence without initiating N9+ or QC outreach.